Agile Therapeutics Inc. (NASDAQ:AGRX) shares saw unusually-high trading volume on Thursday . Approximately 185,150 shares changed hands during trading, an increase of 173% from the previous session’s volume of 67,845 shares.The stock last traded at $7.19 and had previously closed at $6.99.

Several equities research analysts have recently issued reports on the stock. FBR & Co restated a “buy” rating and issued a $17.00 price objective on shares of Agile Therapeutics in a research note on Tuesday, May 10th. Zacks Investment Research upgraded shares of Agile Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research note on Tuesday, May 10th. Cantor Fitzgerald restated a “buy” rating and issued a $18.00 price objective on shares of Agile Therapeutics in a research note on Tuesday, May 10th. Finally, Noble Financial restated a “buy” rating and issued a $15.00 price objective on shares of Agile Therapeutics in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $15.00.

The company has a 50-day moving average of $7.12 and a 200 day moving average of $6.62. The stock’s market capitalization is $206.73 million.

Agile Therapeutics (NASDAQ:AGRX) last released its earnings results on Monday, August 8th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.29). Equities analysts predict that Agile Therapeutics Inc. will post ($1.24) EPS for the current year.

A hedge fund recently raised its stake in Agile Therapeutics stock. Marshall Wace LLP increased its position in Agile Therapeutics Inc. (NASDAQ:AGRX) by 4.9% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 129,769 shares of the specialty pharmaceutical company’s stock after buying an additional 6,099 shares during the period. Marshall Wace LLP owned approximately 0.58% of Agile Therapeutics worth $1,267,000 at the end of the most recent quarter.

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.